posted 10/17/02
Another new treatment option for patients with Type 2 diabetes
who are not in control.
GlaxoSmithKline announced last week that the U.S.
Food and Drug Administration (FDA) approved Avandamet™ (rosiglitazone maleate
and metformin HCl) for the treatment of type 2 diabetes, offering an new option
for millions of Americans with the disease. Avandamet combines two leading
diabetes medications in one convenient pill. This combination offers the
opportunity to help people manage their type 2 diabetes longer. Avandamet will
be available to patients in approximately one month.
"The combination of rosiglitazone and metformin provides two different, yet
complementary mechanisms of action to manage diabetes. "Rosiglitazone targets
insulin resistance, an underlying cause of type 2 diabetes, whereas metformin
works to reduce the amount of blood sugar (or glucose) produced by the liver.
The two medications, when used in combination, target core metabolic defects to
help achieve better blood sugar control than metformin alone, making this an
important option for patients with type 2 diabetes."
"GlaxoSmithKline is committed to developing novel diabetes therapies to treat a
disease that has reached epidemic proportion in the United States and throughout
the world," "With Avandamet, the latest addition to our diabetes portfolio, we
hope to provide an effective, convenient treatment option for people suffering
from uncontrolled type 2 diabetes and also to improve patient compliance”, said
David Brand, Vice President of Metabolic/Endocrine Marketing, GlaxoSmithKline
U.S.. This combination of rosiglitazone and metformin offers the opportunity to
help people manage their type 2 diabetes longer."
The use of rosiglitazone and metformin together as separate tablets was first
approved by the FDA in 1999 as safe and effective based on two controlled
clinical trials in people with type 2 diabetes inadequately controlled on
metformin alone. As an adjunct to diet and exercise, Avandamet is indicated to
improve blood sugar control in people with type 2 diabetes who are already
treated with rosiglitazone and metformin as separate tablets, or who are not
adequately controlled on metformin alone. It is available in three tablet
strengths of rosiglitazone/metformin, respectively: 1 mg/500 mg, 2 mg/500 mg and
4 mg/500 mg. The additive effect of the combination of rosiglitazone and
metformin has been shown to significantly reduce A1C levels compared to
metformin alone. A1C levels are the most effective measure of long-term blood
sugar control. Additionally, it has been shown to successfully impact core
defects of type 2 diabetes, resulting in improvements in both insulin resistance
and estimates of beta-cell function.
In fact, research has demonstrated that rosiglitazone and metformin in
combination significantly reduces and maintains blood sugar levels for up to two
years. The combination has been associated with a low risk of hypoglycemia (low
blood sugar). Avandamet, as a two-in-one therapy, is the most economical
thiazolidinedione (TZD) combination on the market, offering simplified dosing.
Importance of Aggressive Diabetes Management
Diabetes experts are setting more stringent standards that reflect the
importance of maintaining tight glucose control. Based on the United Kingdom
Prospective Diabetes Study (UKPDS) showing that tight blood sugar control can
delay or prevent the complications of type 2 diabetes, the American Diabetes
Association has established an A1C level of no more than 7.0 percent as the
therapeutic target. However, recently, the American Association of Clinical
Endocrinologists and the American College of Endocrinology proposed an A1C
target of 6.5 percent to help reduce the frequency of complications.
"More than 50 percent of people diagnosed with type 2 diabetes do not meet
target A1C levels. And, with every one percent above target A1C levels, a
person's risk for diabetes complications, such as cardiovascular disease,
increases," said Hossein Gharib, M.D., FACE, President of the American
Association of Clinical Endocrinologists. "Therefore, it is critical that we
work to manage diabetes early and aggressively to help ensure that blood sugar
levels are in control."
Avandamet is not indicated for use with insulin. Avandamet should not be used in
patients with renal disease or dysfunction or with congestive heart failure
requiring medication. Before using Avandamet, patients over the age of 80 should
have their renal function tested to assure that their kidney function is
adequate. Avandamet is not recommended for people with liver disease. Patients
should inform their doctor if they drink alcohol excessively. Tests should be
conducted before and while taking Avandamet to check for liver problems.
Source: Diabetes In Control Dot Com: GlaxoSmithKline.
Home - Table of Contents - Donate Now - About Diabetes - Warning Signs - Complications - Screening Test - Diabetes Terms - Site Search - Meet Mr. Diabetes® - Wake Up And Walk® Tour - Latest News - Headlines & News Stories - Health & Fitness - About Us - FAQ - Research Form - - Message Board - Privacy Policy - Legal Notices - How to Contact Us - Comments form - Suggestion Form - Our E-Mail Addresses - Our Address and Phone Numbers - Links - Contact Us